TEREBYO 14 mg, film-coated tablet 28 tablets
Active ingredients: Teriflunomide
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet28 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TEREBYO 14 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) OPA : polyamide orienté aluminium PVC-Aluminium de 28 comprimé(s) sous étuis
- Marketing authorisation holder
- SANDOZ
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 11 Jan 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
69421610CIP73026491CIP133400930264911Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| TÉRIFLUNOMIDEcomprimé | 14 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.